Xinhua news agency, Tianjin, November 5 (reporter Qu Ting, Zhang Jianxin) coronary stents of up to 10000 yuan have entered the "thousand Yuan era". The reporter learned from the joint procurement office of high-value medical consumables of the state organization that the first batch of high-value medical consumables purchased from coronary stents were selected in Tianjin on November 5. The price of coronary stent decreased from about 13000 yuan to 700 yuan.
It is reported that the coronary stents purchased in this concentrated volume are cobalt chromium alloy or platinum chromium alloy, and the drug loading types are rapamycin and its derivatives, and the procurement cycle is two years. The mainstream products commonly used in clinical practice of medical institutions are basically selected, covering more than 70% of the intended purchase volume of medical institutions. Compared with that in 2019, the average price reduction of the same products of the same enterprise is 93%, that of domestic products is 92%, and that of imported products is 95%. It is estimated that 10.9 billion yuan of related expenses will be saved according to the amount of intended purchase.
The reporter learned that relevant enterprises actively participated in the centralized procurement, and a total of 11 enterprises participated in the bidding, involving 26 coronary stent products registered and listed in China. Through competition, 10 products are selected, which belong to 8 Chinese and foreign enterprises. Medical institutions also actively participated in the centralized purchase, involving 2408 medical institutions, including 851 medical institutions with annual purchase volume of more than 500. In the first year, the intended purchase volume reached 1.07 million, which was close to the purchase quantity of drug loaded chromium alloy stent in 2019 (1.09 million), accounting for 65% of the total material procurement in 2019 (1.65 million).
Zhong Dongbo, director of the medical price and bidding procurement department of the State Medical Security Bureau, evaluated the results of the national centralized procurement of coronary stents as: let the common people benefit, let the medical institutions be encouraged, and promote the high-quality development of the pharmaceutical industry. According to reports, the state's organization of centralized procurement of coronary stents is an important measure to control the virtual high price and disordered circulation of high-value medical consumables, and is a key link in comprehensively deepening the reform of centralized procurement in the medical field. The substantial reduction of purchase price will significantly reduce the burden of medical expenses of the masses. It is expected that patients throughout the country will use the selected products after the national centralized purchase price reduction in January 2021.